Following a positive recommendation from Europe’s Committee for Medicinal Products for Human Use (CHMP), the European Commission on Monday 19th December formally approved Atara Biotherapeutics ...

Story March 4 - Atara Biotherapeutics: While the biotech navigates the fallout from the FDA’s move to halt trials of its allogeneic T-cell immunotherapy Ebvallo and a CAR-T candidate ...

Stifel Nicolaus analyst Benjamin Burnett maintained a Hold rating on Atara Biotherapeutics (ATRA – Research Report) yesterday and set a price ...

TD Cowen analyst Phil Nadeau maintained a Buy rating on Atara Biotherapeutics (ATRA – Research Report) yesterday. The company’s shares closed ...

Revenue: US$128.9m (up by US$120.4m from FY 2023). Net loss: US$85.4m (loss narrowed by 69% from FY 2023). US$11.41 loss per share (improved from US$65.18 loss in FY 2023). Revenue exceeded ...

Atara Biotherapeutics Inc (ATRA) has disclosed a new risk, in the Corporate Activity and Growth category. Atara Biotherapeutics Inc faces ...

After hours: March 13 at 5:39:14 PM EDT Loading Chart for ATRA ...

With cutting-edge technology, a robust regulatory framework, and a highly skilled team, BTCF is committed to driving innovation in cell therapy research and clinical translation, helping to bring next ...